| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
For nearly 50 years, Acts Retirement-Life Communities has met the retirement lifestyle and healthcare needs of older adults living in our communities. Our first community opened in 1972 with the vision of a church pastor and his congregation whose goal was to create an environment that offered seniors a rewarding lifestyle and high quality healthcare if ever needed. Today, Acts is the largest not-for-profit owner, operator and developer of continuing care retirement communities (CCRCs) in the United States. Our 26 communities currently serve more than 10,000 residents in nine states. Our vision for Acts is to have The Acts Culture of Loving-Kindness be the basic fiber of our daily practice to meet the needs of those we serve. As we continue to grow, we`re looking for dedicated and compassionate individuals to join our team who help to carry out our mission of serving older adults. We have been able to provide an unparalleled quality of life for our residents by recruiting and hiring great people who understand our vision and strive to be a part of it. We are convinced that the secret to our success is our employees who work as a team each day to make a positive difference in the lives of our residents. It is for this reason that we provide a working environment based on fair employment practices, competitive pay and benefits, career opportunities and other programs designed to help our employee`s achieve their professional goals.
Watson Clinic is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Watson Clinic is based in Lakeland, FL. You can find more information on Watson Clinic at www.watsonclinic.com
Trusted by more than 50,000 customers, Briggs has been helping health care providers improve clinical and financial performance through a wide array of products for more than 60 years.
Denver-Vail Orthopedics is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.